You are here

New AAN Guideline on Treatment of Chorea in Huntington’s Disease

Huntington’s disease is a complex disorder with physical, cognitive, and behavioral symptoms. The new guideline addresses only one aspect of the disease that may require treatment.

“Chorea can be disabling, worsen weight loss, and increase the risk of falling,” said Melissa Armstrong, MD, MSc, the guideline’s lead author. According to the new statement, tetrabenazine (TBZ), riluzole, and amantadine may be helpful for treating chorea, and nabilone may also be considered. Riluzole, amantadine, and nabilone are not often prescribed for Huntington’s disease.

“People with Huntington’s disease who have chorea should discuss with their doctors whether treating chorea is a priority,” Dr. Armstrong said “Huntington’s disease is complex, with a wide range of sometimes severe symptoms, and treating other symptoms may be a higher priority than treating chorea.”

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut
Modified gold-based molecules show promise as effective, targeted treatment
Vitamin E Found in Samples Around the Country